A Phase I Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of STS101 5.2 mg and Two Higher Dose Strengths

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2021 According to a Satsuma Pharmaceuticals media release, data from this study will support the SUMMIT trial.
16 Jun 2021 Results presented in a Satsuma Pharmaceuticals media release.
11 May 2021 According to a Satsuma Pharmaceuticals media release, the company anticipates completing this Phase 1 trial in the second quarter of 2021 and based on trial results, plans to select the STS101 dose strength to evaluate in the new Phase 3 SUMMIT trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com